News
Jefferies initiates analytical coverage of Celon Pharma
Jefferies initiates analytical coverage of Celon Pharma, with the recommendation: Buy and the target price of PLN 37.50. The report is available to Jefferies customers. Lucy Codrington, MBChB | Equity Analyst, European HealthcareJefferies International Ltd | 100 Bishopsgate | London | EC2N 4JL |[email protected]
March 11, 2022 – Current report no. 6/2022 – Wydanie 30.000 akcji serii C w ramach warunkowego podwyższenia kapitału zakładowego
The Management Board of Celon Pharma S.A. (“Company”) informs that on March 11, 2022, 30,000 series C shares of the Company, with a nominal value of PLN 0.10 each, were entered in the securities accounts of the entitled persons, as part of the conditional increase of the Company’s share capital (“Shares”). The Shares were takenRead more »
February 21, 2022 – Current Report no. 5/2022 – Conclusion of a license purchase agreement
Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.Date: February 21, 2022, time: 22:18 p.m.The Management Board of Celon Pharma S.A. (“Company”) informs that on February 20, 2022, it learned about the conclusion of an agreement with the Salk Institute for Biological Studies (“Salk”) on the purchase of a
Legal basis: Article 56 section 1 point 2 Act on Public Offering – current and periodic information.Date: February 16, 2022.The abbreviated name of the issuer CELON PHARMA S.A.Subject: The KDPW statement on concluding an agreement on the registration of the Company’s series C shares The Management Board of Celon Pharma SA (the “Company”) hereby informsRead more » Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Date: January 21, 2022, time: 05:08 p.m. The Management Board of Celon Pharma S.A. (“Company”) announces that on January 21, 2022, it learned about the inclusion of the first patient in the Phase II clinical trial of CPL’280, a second-generationRead more » This year, from November 8-11, the jubilee, 50th edition of the conference organized by the Society for Neuroscience – the world’s largest organization of scientists and doctors dealing with brain diseases will take place. Despite the fact that the event is planned in the online formula, the organizers have planned numerous lectures, poster sessions andRead more » Representatives of the Management Board of Celon Pharma S.A. will take part in the 12th edition of the largest European conference on life science. The 34th ECNP Congress will take place on October 2-5 in Lisbon. This is the most important European scientific meeting dedicated to brain research for disease. Each year, this event attracts over 5,000 psychiatrists, neurologists and psychologists from around the world. During the 34th ECNP Congress, posters will be presented. Posters by Sylwia Janowska –Read more » The EASD Annual Meeting is one of the largest scientific congresses, presenting the latest results from basic and clinical diabetes research and the place to meet the global diabetes community.
February 16, 2022 – Current Report No. 4/2022 – The KDPW statement on concluding an agreement on the registration of the Company’s series C shares
January 21, 2022 – Current Report No. 3/2022 – Phase II clinical trial of CPL’280 in treatment of type 2 diabetes commenced
The results of CPL’36 – PDE10a inhibitor to be presented in the poster session at Neuroscience 2021.
Celon Pharma S.A. at the Jefferies Healthcare Conference 2021.
3 posters to be published at 34th ECNP Congress
Celon Pharma at EASD 2021